[ad_1]
Bala Cynwyd, Pa., March 6, 2024 (GLOBE NEWSWIRE) — Larimar Therapeutics, Inc. (“Larimar”) (NASDAQ: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today Announced that members of the company’s management team will present and participate in a 1×1 investor conference at the Leerink Partners Global Biopharmaceutical Conference, to be held in Miami Beach, Florida, from March 11-13, 2024.
See below for details on the demo.
Date: Wednesday, March 13, 2024
Time: 10 a.m. ET
Webcast link: https://wsw.com/webcast/leerink33/lrmr/2241008
After the presentation, a replay will be available for 30 days on the Events & Presentations page of the Larimar website.
About Lalima Therapy
Larimar Therapeutics, Inc. (Nasdaq: LRMR) is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. Larimar’s lead compound, nomlabofusp, is being developed as a potential treatment for Friedreich’s ataxia. Larimar also plans to use its intracellular delivery platform to design other fusion proteins to target other rare diseases characterized by deficiencies in intracellular bioactive compounds. For more information, please visit: https://larimartx.com.
Investor contact information:
Joyce Allaire
life sciences consultant
jallaire@lifesciadvisors.com
(212) 915-2569
Company contact information:
Michael Serrano
chief financial officer
mcelano@larimartx.com
(484)414-2715
[ad_2]
Source link